2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of …
Writing Committee, MM Kittleson, FL Ruberg… - Journal of the American …, 2023 - jacc.org
The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients
Cochrane, Maria Crespo Leiro, Anne Dipchand, Brian Feingold, Kathleen Grady, Edward
Horn, Maryl Johnson, Donna Mancini, Sean Pinney, Heather Ross, Kari Wujcik, Andreas …
Horn, Maryl Johnson, Donna Mancini, Sean Pinney, Heather Ross, Kari Wujcik, Andreas …
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung …
DC Chambers, WS Cherikh, MO Harhay… - The Journal of Heart …, 2019 - jhltonline.org
This 36th adult lung and heart-lung transplant report summarizes data from 69,200 adult
lung and 4,128 adult heart-lung transplants performed through June 30, 2018 and reported …
lung and 4,128 adult heart-lung transplants performed through June 30, 2018 and reported …
[HTML][HTML] T2 mapping in myocardial disease: a comprehensive review
Cardiovascular magnetic resonance (CMR) is considered the gold standard imaging
modality for myocardial tissue characterization. Elevated transverse relaxation time (T2) is …
modality for myocardial tissue characterization. Elevated transverse relaxation time (T2) is …
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; …
KK Khush, L Potena, WS Cherikh… - The Journal of Heart …, 2020 - jhltonline.org
Heart transplantation continues to be limited by a paucity of donor organs despite
innovations in organ procurement and organ preservation, greater willingness to accept …
innovations in organ procurement and organ preservation, greater willingness to accept …
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist …
MR Mehra, JC Cleveland Jr, N Uriel… - European journal of …, 2021 - Wiley Online Library
Aim The MOMENTUM 3 pivotal trial established superiority of the HeartMate 3 (HM3) left
ventricular assist device (LVAD), a fully magnetically levitated centrifugal‐flow pump, over …
ventricular assist device (LVAD), a fully magnetically levitated centrifugal‐flow pump, over …